---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-026690"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:22:53.323310+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Clene reports Q2 net loss $7.4M, cash $7.3M, plans NDA submission for CNM-Au8 in ALS by end of 2025

## Summary
- Net loss of $7.4M ($0.78 per share) vs $6.8M ($1.06) in Q2 2024; R&D expenses $3.5M, G&A $2.4M.
- Cash and equivalents $7.3M as of June 30, 2025; post-quarter $1.9M equity and $1.5M convertible debt funding provides runway into Q1 2026.
- FDA meetings scheduled: Type C for survival data in Q3 2025, and analysis of NfL biomarker from NIH EAP early Q4 2025.
- Plans to submit NDA for CNM-Au8 in ALS under accelerated approval by end of 2025.
- End-of-Phase 2 Type B meeting with FDA for MS program planned in Q3 2025.

## SEC filing metadata
- accession: 0001437749-25-026690
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/0001437749-25-026690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/clnn20250611_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-026690
- JSON: https://secwatch.observer/filing/0001437749-25-026690.json
- Plain text: https://secwatch.observer/filing/0001437749-25-026690.txt

## Key facts
- Debt Financings
  Clene Inc. incurred convertible notes of $1,500,000 aggregate principal amount with AE Capital Limited; A Global Chorus Foundation; Glenn and Shelina Way at 12% per annum, interest capitalized and added to principal balance maturing earlier of 18 months from closing or Change in Control.
  - Instrument: convertible notes
  - Principal: $1,500,000 aggregate principal amount
  - Counterparty: AE Capital Limited; A Global Chorus Foundation; Glenn and Shelina Way
  - Rate: 12% per annum, interest capitalized and added to principal balance
  - Maturity: earlier of 18 months from closing or Change in Control
  - Event: incurrence
  source text: On August 13, 2025, the Company entered into a note purchase agreement (the “August 2025 Note Purchase Agreement”) by and among the Company and AE Capital Limited, A Global Chorus Foundation and Glenn and Shelina Way (together with AE Capital Limited and A Global Chorus Foundation, the “August 2025 Note Purchasers”), pursuant to which the Company agreed to sell, and the August 2025 Note Purchasers agreed to purchase, the Company’s senior secured convertible promissory notes (collectively, the “ August 2025 Notes”) in a principal amount totaling $1,500,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/0001437749-25-026690-index.htm
- Debt Financings
  Clene Inc. amended convertible notes of original principal amounts unchanged (December 2024 Notes); monthly principal repayments of $1,000,000 per month deferre with Kensington Clene 2024, LLC; 4Life Research, LLC; La Scala Investments, LLC at interest capitalized and added to balance from August 1, 2025; at holder electio maturing maturity extended to earlier of February 13, 2027 or Change in Control.
  - Instrument: convertible notes
  - Principal: original principal amounts unchanged (December 2024 Notes); monthly principal repayments of $1,000,000 per month deferre
  - Counterparty: Kensington Clene 2024, LLC; 4Life Research, LLC; La Scala Investments, LLC
  - Rate: interest capitalized and added to balance from August 1, 2025; at holder electio
  - Maturity: maturity extended to earlier of February 13, 2027 or Change in Control
  - Event: amendment
  source text: On August 13, 2025, Clene Inc. (the “Company”) entered into the first amendment (the “Amendment”) to the senior secured convertible promissory notes (collectively, the “December 2024 Notes”) which were issued by the Company on December 17, 2024 to Kensington Clene 2024, LLC (“Kensington”), 4Life Research, LLC (“4Life”) and La Scala Investments, LLC (“La Scala,” and collectively with Kensington and 4Life, the “December 2024 Note Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/0001437749-25-026690-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.